We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: AMN Healthcare Services is a travel healthcare staffing company. It recruits and places nurses, physicians, and other healthcare professionals in travel or permanent assignments in acute-care facilities, physician practice groups, and other healthcare facilities. The company currently reports through three segments: Nurse and Allied Solutions, Locum Tenens Solutions and Other Workforce Solutions. Nurse and Allied Solutions provides services for acute-care facility, permanent staff nurses for medical practice and experienced home care nurse staffing, interim nurse leaders. Locums Tenens Solutions physicians can act during staffing gaps created by vacancies, vacations and periods of high demand. Meanwhile, Workforce Solutions offers the most comprehensive suite of innovative workforce solutions, ranging from traditional staffing and recruitment to managed services programs, vendor management systems, in-house resource pool management and recruitment process outsourcing.
- Recent AMN Stock Price: $68.50
- Yearly Gain for AMN stock: -40.23%
- Market Cap for AMN stock: $2.76B
- P/E Ratio for AMN stock: 10.276
Will AMN's stock price go up? Is there an accurate AMN stock forecast available?
TipRanks.com reports that AMN Healthcare Services currently has 5 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $80.20. The target pricing ranges from a high AMN forecast of $88 down to a low forecast of $70. AMN Healthcare Services (AMN)’s last closing stock price was $68.50 which would put the average price target at 19.08% upside.
In addition, TradingView issued a Sell rating for AMN stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on AMN stock.
Other analysts covering AMN include:
- Jeffrey Silber of BMO Capital issued a Buy rating with the price target of $85 on 2 days ago
- Tobey Sommer of Truist Financial issued a Buy rating with the price target of $88 on 2 days ago
- A.J. Rice of UBS issued a Hold rating with the price target of $73 on 1 week ago
- Brian Tanquilut of Jefferies issued a Hold rating with the price target of $70 on 1 month ago
If you are wondering if AMN is a good stock to buy, here are 3rd party ratings for AMN stock:
- TipRanks.com: Moderate Buy
- TradingView.com: Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Top 35% (87 out of 251)
What is the sentiment on the street regarding AMN Healthcare Services? (Current ratings compiled by TipRanks.com)
- News Sentiment for AMN stock: Very Bullish
- Blogger Consensus for AMN stock: Bullish
- Media Buzz for AMN stock: Very High
- Insider Signal for AMN stock: Negative
- Investor Sentiment for AMN stock: Very Negative
- Hedge Fund signal for AMN stock: Positive
The stock market is extremely volatile, and you need to do your own research on AMN stock including scouring the social networks like AMN StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for AMN stock chart >>
Summary: Repro-Med Systems Inc. is engaged in the design and manufacture of medical devices directing resources to the global markets for emergency medical products and infusion therapy.
- Recent KRMD Stock Price: $2.28
- Yearly Gain for KRMD stock: -28.70%
- Market Cap for KRMD stock: $108.24M
- P/E Ratio for KRMD stock: -12.741
Will KRMD's stock price go up? Is there an accurate KRMD stock forecast available?
TipRanks.com reports that REPRO-MED Systems currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $3.50. The target pricing ranges from a high KRMD forecast of $4.5 down to a low forecast of $2.5. REPRO-MED Systems (KRMD)’s last closing stock price was $2.28 which would put the average price target at 53.51% upside.
In addition, TradingView issued a Sell rating for KRMD stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on KRMD stock.
Other analysts covering KRMD include:
- Frank Takkinen of Lake Street issued a Buy rating with the price target of $4 on 18 hours ago
- Jason Bednar of Piper Sandler issued a Buy rating with the price target of $2.5 on 18 hours ago
- Neil Chatterji of B.Riley Financial issued a Buy rating with the price target of $4.5 on 3 weeks ago
- Caitlin Cronin of Canaccord Genuity issued a Buy rating with the price target of $3 on 4 weeks ago
If you are wondering if KRMD is a good stock to buy, here are 3rd party ratings for KRMD stock:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Buy, Top 29% (74 out of 251)
What is the sentiment on the street regarding REPRO-MED Systems? (Current ratings compiled by TipRanks.com)
- News Sentiment for KRMD stock: Very Bullish
- Blogger Consensus for KRMD stock: Neutral
- Media Buzz for KRMD stock: Low
- Insider Signal for KRMD stock: ―
- Investor Sentiment for KRMD stock: ―
- Hedge Fund signal for KRMD stock: Neutral
The stock market is extremely volatile, and you need to do your own research on KRMD stock including scouring the social networks like KRMD StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for KRMD stock chart >>
Summary: Arvinas Inc. is a biopharmaceutical company for patients suffering from debilitating and life-threatening diseases. It engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Arvinas Inc. is based in CT, United States.
- Recent ARVN Stock Price: $30.30
- Yearly Gain for ARVN stock: -36.95%
- Market Cap for ARVN stock: $1.33B
- P/E Ratio for ARVN stock: -4.193
Will ARVN's stock price go up? Is there an accurate ARVN stock forecast available?
TipRanks.com reports that Arvinas Holding Company currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $60.00. The target pricing ranges from a high ARVN forecast of $95 down to a low forecast of $33. Arvinas Holding Company (ARVN)’s last closing stock price was $30.30 which would put the average price target at 74.49% upside.
In addition, TradingView issued a Strong Buy rating for ARVN stock over the next month, Barchart.com has a Weak buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on ARVN stock.
Other analysts covering ARVN include:
- Andrew Fein of H.C. Wainwright issued a Buy rating with the price target of $90 on 18 hours ago
- Robert Driscoll of Wedbush issued a Buy rating with the price target of $33 on 1 day ago
- Bradley Canino of Stifel Nicolaus issued a Buy rating with the price target of $42 on 6 days ago
- Matthew Biegler of Oppenheimer issued a Buy rating with the price target of $95 on 1 week ago
If you are wondering if ARVN is a good stock to buy, here are 3rd party ratings for ARVN stock:
- TipRanks.com: Strong Buy
- TradingView.com: Strong Buy
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Weak buy
- Zacks.com: Hold, Top 24% (59 out of 251)
What is the sentiment on the street regarding Arvinas Holding Company? (Current ratings compiled by TipRanks.com)
- News Sentiment for ARVN stock: Neutral
- Blogger Consensus for ARVN stock: Bullish
- Media Buzz for ARVN stock: Very Low
- Insider Signal for ARVN stock: ―
- Investor Sentiment for ARVN stock: Neutral
- Hedge Fund signal for ARVN stock: Positive
The stock market is extremely volatile, and you need to do your own research on ARVN stock including scouring the social networks like ARVN StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for ARVN stock chart >>
Summary: Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates engineered to increase muscle function and contractility. Cytokinetics' lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the FDA and orphan medicinal product designation by the EMA. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure, and with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy.
- Recent CYTK Stock Price: $33.46
- Yearly Gain for CYTK stock: -12.00%
- Market Cap for CYTK stock: $3.32B
- P/E Ratio for CYTK stock: -5.897
Will CYTK's stock price go up? Is there an accurate CYTK stock forecast available?
TipRanks.com reports that Cytokinetics currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $66.80. The target pricing ranges from a high CYTK forecast of $80 down to a low forecast of $50. Cytokinetics (CYTK)’s last closing stock price was $33.46 which would put the average price target at 82.52% upside.
In addition, TradingView issued a Buy rating for CYTK stock over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on CYTK stock.
Other analysts covering CYTK include:
- Yasmeen Rahimi of Piper Sandler issued a Buy rating with the price target of $69 on 1 day ago
- Paul Choi of Goldman Sachs issued a Buy rating with the price target of $50 on 3 days ago
- Salim Syed of Mizuho Securities issued a Buy rating with the price target of $80 on 5 days ago
- Jeffrey Hung of Morgan Stanley issued a Buy rating with the price target of $60 on 2 weeks ago
If you are wondering if CYTK is a good stock to buy, here are 3rd party ratings for CYTK stock:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Weak sell
- Zacks.com: Sell, Top 24% (59 out of 251)
What is the sentiment on the street regarding Cytokinetics? (Current ratings compiled by TipRanks.com)
- News Sentiment for CYTK stock: Very Bullish
- Blogger Consensus for CYTK stock: Bullish
- Media Buzz for CYTK stock: Low
- Insider Signal for CYTK stock: Negative
- Investor Sentiment for CYTK stock: Very Positive
- Hedge Fund signal for CYTK stock: Neutral
The stock market is extremely volatile, and you need to do your own research on CYTK stock including scouring the social networks like CYTK StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for CYTK stock chart >>
Summary: Olema Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It engages in discovery, development and commercialization of therapies for women's cancers. The company's product pipeline includes OP-1250, which is in clinical stage. Olema Pharmaceuticals Inc. is based in San Francisco, California.
- Recent OLMA Stock Price: $11.72
- Yearly Gain for OLMA stock: 418.47%
- Market Cap for OLMA stock: $835.24M
- P/E Ratio for OLMA stock: -5.555
Will OLMA's stock price go up? Is there an accurate OLMA stock forecast available?
TipRanks.com reports that Olema Pharmaceuticals currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $24.80. The target pricing ranges from a high OLMA forecast of $28 down to a low forecast of $21. Olema Pharmaceuticals (OLMA)’s last closing stock price was $11.72 which would put the average price target at 116.13% upside.
In addition, TradingView issued a Sell rating for OLMA stock over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on OLMA stock.
Other analysts covering OLMA include:
- Matthew Biegler of Oppenheimer issued a Buy rating with the price target of $21 on 18 hours ago
- Sam Slutsky of LifeSci Capital issued a Buy rating with the price target of $26 on 1 day ago
- William Maughan of Canaccord Genuity issued a Buy rating with the price target of $24 on 1 day ago
- Michael Yee of Jefferies issued a Buy rating with the price target of $25 on 1 week ago
If you are wondering if OLMA is a good stock to buy, here are 3rd party ratings for OLMA stock:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Hold, Top 24% (59 out of 251)
What is the sentiment on the street regarding Olema Pharmaceuticals? (Current ratings compiled by TipRanks.com)
- News Sentiment for OLMA stock: Very Bullish
- Blogger Consensus for OLMA stock: Bullish
- Media Buzz for OLMA stock: Very High
- Insider Signal for OLMA stock: Negative
- Investor Sentiment for OLMA stock: Very Positive
- Hedge Fund signal for OLMA stock: Positive
The stock market is extremely volatile, and you need to do your own research on OLMA stock including scouring the social networks like OLMA StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for OLMA stock chart >>
Summary: Vertex Pharmaceuticals Incorporated is focused on the discovery, development, and commercialization of small molecule drugs targeting serious diseases. The company's main area of focus is cystic fibrosis. The company's lead marketed products are Trikafta, Symdeko/Symkevi, Orkambi and Kalydeco, which are collectively approved to treat the people with CF in North America, Europe and Australia. Trikafta, Vertex's triple combination regimen, was approved by the FDA for the treatment of CF in people aged 12 years and older who have at least one F508del mutation. While CF remains the main area of focus, Vertex is also developing treatments for sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency and muscular dystrophies. Pimodivir/VX-787, for the treatment of influenza, was out-licensed to Janssen while oncology candidates VX-970, VX-984 and VX-803 were divested to Merck KGaA.
- Recent VRTX Stock Price: $353.46
- Yearly Gain for VRTX stock: 13.58%
- Market Cap for VRTX stock: $90.35B
- P/E Ratio for VRTX stock: 26.58
Will VRTX's stock price go up? Is there an accurate VRTX stock forecast available?
TipRanks.com reports that Vertex Pharmaceuticals currently has 4 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $394.75. The target pricing ranges from a high VRTX forecast of $425 down to a low forecast of $359. Vertex Pharmaceuticals (VRTX)’s last closing stock price was $353.46 which would put the average price target at 10.78% upside.
In addition, TradingView issued a Sell rating for VRTX stock over the next month, Barchart.com has a Weak buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on VRTX stock.
Other analysts covering VRTX include:
- Olivia Brayer of Cantor Fitzgerald issued a Buy rating with the price target of $380 on 1 day ago
- Mohit Bansal of Wells Fargo issued a Buy rating with the price target of $425 on 3 days ago
- Sasikarn Udomvej of DBS issued a Hold rating with the price target of $359 on 5 days ago
If you are wondering if VRTX is a good stock to buy, here are 3rd party ratings for VRTX stock:
- TipRanks.com: Moderate Buy
- TradingView.com: Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Weak buy
- Zacks.com: Hold, Top 24% (59 out of 251)
What is the sentiment on the street regarding Vertex Pharmaceuticals? (Current ratings compiled by TipRanks.com)
- News Sentiment for VRTX stock: Very Bullish
- Blogger Consensus for VRTX stock: Bullish
- Media Buzz for VRTX stock: Medium
- Insider Signal for VRTX stock: ―
- Investor Sentiment for VRTX stock: Positive
- Hedge Fund signal for VRTX stock: Very Positive
The stock market is extremely volatile, and you need to do your own research on VRTX stock including scouring the social networks like VRTX StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for VRTX stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
==============================================================================
